AbbVie's Skyrizi Cleared for Pediatric Psoriasis in Europe
The European Commission has authorized the use of Skyrizi for children and adolescents as young as six suffering from moderate to severe plaque psoriasis. The approval introduces a specialized 55 mg pre-filled syringe, enabling precise weight-based dosing for younger patients who weigh less than 40 kilograms.
























